Search for European Projects

11 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)

Start date: Mar 1, 2015, End date: Feb 29, 2020,

...ew assays which might potentially used for future clinical trials for influenza seasonal vaccine evaluationFLUCOP Consortium and Project Impact: The FLUCOP consortium brings together 26 groups from 7 European countries, and includes contributors from the academic, governmental, non-for-profit and pharmaceutical sectors. As a whole, the consortium has a balanced array of expertise and each group ha ...
Read Project

 26

 FINISHED 

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure (EDUFLUVAC)

Start date: Nov 1, 2013, End date: Oct 31, 2017,

"As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC ai ...
Read Project

 9

 FINISHED 

A Multi-Stage Malaria Vaccine (MultiMalVax)

Start date: Oct 1, 2012, End date: Mar 31, 2017,

...ccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure efficacy prior to field testing. This SME-led collaboration of a leading SME, two universities, the major European product development partnership for malaria vaccines, and a global pharmaceutical company will provide complementary abilities to accelerate development of this promising product.
Read Project

 6

 FINISHED 

Clinical development of a VAR2CSA-based placental malaria vaccine (PLACMALVAC)

Start date: Mar 1, 2013, End date: Feb 28, 2017,

...d they have been collaborating with Institut de Recherche pour le Developpement (IRD) and Université d'Abomey-Calavi (UAC) to optimize vaccine antigens and to prepare sites for clinical testing. The European Vaccine Initiative (EVI) will provide product management and coordinate execution of the phase I clinical trial. Thus, this study will provide a product to continue into efficacy studies in Af ...
Read Project

 6

 FINISHED 

comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN (BELLEROPHON)

Start date: Sep 1, 2013, End date: Aug 31, 2016,

"Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals.Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to ...
Read Project

 4

 FINISHED 

Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE)

Start date: Dec 1, 2013, End date: Mar 31, 2016,

Under the leadership of the major Europe-based vaccine industry players, IPROVE (Innovation Partnership for a Roadmap on Vaccines in Europe) will produce a comprehensive roadmap on the future of vaccine R&D, production and delivery in the EU. IPROVE aims to drive current EU research efforts towards the establishment of a clear vision of the priority innovations and technologies necessary to addres ...
Read Project

 5

 FINISHED 

Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA)

Start date: Mar 1, 2010, End date: Aug 31, 2015,

...by worm co-infections of vaccine-induced immune responses. To achieve these objectives, IDEA project has developed a global and innovative strategy which includes: a) the alliance between African and European leading scientists in the field of worms, HIV, TB and malaria, b) the multidisciplinary expertise involving immunologists, parasitologists, epidemiologists, clinicians, and experts in vaccine ...
Read Project

 23

 FINISHED 

European Network of Vaccine Development and Research (TRANSVAC)

Start date: Oct 1, 2009, End date: Sep 30, 2013,

...guably, fragmentation of expertise and facilities has slowed, and in some instances distinctly impeded, the development and validation of promising vaccine candidates. To address these challenges the European vaccine development community needs to establish a collaborative vaccine development infrastructure based on shared visions and goals. The European Vaccine Initiative (EVI) and the Tuberculos ...
Read Project

 18

 FINISHED 

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation (OPTIMALVAC)

Start date: Apr 1, 2009, End date: Mar 31, 2012,

"A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidem ...
Read Project

 14

 FINISHED 

"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges." (INYVAX)

Start date: Feb 1, 2009, End date: Jan 31, 2012,

...re-clinical criteria. 3) the development of information-sharing tools to strengthen connections between the scientists, the developers and the clinical investigators. To address those challenges, the European vaccine community needs to establish a shared vision and goals and to identify the activities that could address some of the above-mentioned challenges. The cooperation between the different ...
Read Project

 10

 FINISHED 

Platform for the Harmonization of Vaccine Adjuvant Testing (PHARVAT)

Start date: Nov 1, 2009, End date: Oct 31, 2011,

"Adjuvants are critical to the quality and magnitude of immune responses generated by PRD vaccines. However, vaccine development is hampered by lack of access to appropriate adjuvants. This is partly because adjuvants are developed in many organizations, with individual models and protocols that have been established independently. The resulting data on adjuvants are only rarely directly comparabl ...
Read Project

 4